TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences Ltd announced the issuance of 3,333,332 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company confirmed compliance with relevant provisions of the Corporations Act and stated there is no excluded information to disclose. This move supports Rhythm’s ongoing efforts in enhancing its financial position to further develop and distribute its diagnostic products, potentially impacting its market presence positively.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple and affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes by detecting cancers at the earliest possible stage, thereby reducing the global cancer burden. Rhythm collaborates with global partners to commercialize and distribute its solutions.
Average Trading Volume: 343,535
Technical Sentiment Signal: Buy
Current Market Cap: A$28.99M
For an in-depth examination of RHY stock, go to TipRanks’ Overview page.